, Guidelines for the clinical management and treatment of HIV infected adults in Europe, European AIDS clinical society, p.31, 2015.

A. J. Claxton, J. Cramer, and C. Pierce, A systematic review of the associations between dose regimens and medication compliance, Clin Ther, vol.23, p.11558866, 2001.

J. Parienti, D. R. Bangsberg, R. Verdon, and E. M. Gardner, Better adherence with once-daily antiretroviral regimens: a meta-analysis, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.48, pp.484-488, 2009.

M. Goicoechea and B. Best, Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?, Expert Opin Pharmacother, vol.8, p.17266471, 2007.

B. Killingley and A. Pozniak, The first once-daily single-tablet regimen for the treatment of HIV-infected patients. Drugs Today Barc Spain, vol.43, pp.427-442, 1998.

J. E. Gallant, E. Dejesus, J. R. Arribas, A. L. Pozniak, B. Gazzard et al., Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV, N Engl J Med, vol.354, pp.251-260, 2006.

I. Aldir, A. Horta, and M. Serrado, Single-tablet regimens in HIV: does it really make a difference, Curr Med Res Opin, vol.30, pp.89-97, 2014.

N. Astuti and F. Maggiolo, Single-Tablet Regimens in HIV Therapy, Infect Dis Ther, vol.3, pp.1-17, 2014.

M. A. Thompson, M. J. Mugavero, K. R. Amico, V. A. Cargill, L. W. Chang et al., Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel, Ann Intern Med, vol.156, p.22393036, 2012.

D. R. Bangsberg, K. Ragland, A. Monk, and S. G. Deeks, A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people, AIDS Lond Engl, vol.24, pp.2835-2840, 2010.

A. Buscher, C. Hartman, M. A. Kallen, and T. P. Giordano, Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients, Int J STD AIDS, vol.23, pp.351-355, 2012.

T. Juday, S. Gupta, K. Grimm, S. Wagner, and E. Kim, Factors associated with complete adherence to HIV combination antiretroviral therapy, HIV Clin Trials, vol.12, pp.71-78, 2011.

G. Sterrantino, L. Santoro, D. Bartolozzi, M. Trotta, and M. Zaccarelli, Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era, Patient Prefer Adherence, vol.6, p.22723727, 2012.

M. Airoldi, M. Zaccarelli, L. Bisi, T. Bini, A. Antinori et al., One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects, Patient Prefer Adherence, vol.4, p.20517472, 2010.

A. Ganguli, J. Wang, and D. R. Gourley, Does combining antiretroviral agents in a single dosage form enhance quality of life of HIV/AIDS patients? A cost-utility study, Res Soc Adm Pharm RSAP, vol.8, pp.157-165, 2012.

P. E. Sax, J. L. Meyers, M. Mugavero, and K. L. Davis, Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States, PloS One, vol.7, p.31591, 2012.

M. Gandhi and R. T. Gandhi, Single-pill combination regimens for treatment of HIV-1 infection, N Engl J Med, vol.371, pp.248-259, 2014.

P. Pugliese, L. Cuzin, A. Cabié, I. Poizot-martin, C. Allavena et al., A large French prospective cohort of HIV-infected patients: the Nadis Cohort, HIV Med, vol.10, p.19486189, 2009.

P. E. Sax, C. Tierney, A. C. Collier, E. S. Daar, K. Mollan et al., Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results, J Infect Dis, vol.204, pp.1191-1201, 2011.

F. Kwiatkowski, K. Slim, P. Verrelle, E. Chamorey, and A. Kramar, Bull Cancer (Paris), vol.94, pp.680-686, 2007.

F. Raffi, Y. Yazdanpanah, F. Fagnani, C. Laurendeau, A. Lafuma et al., Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database, J Antimicrob Chemother, vol.70, pp.2121-2128, 2015.

A. Antinori, C. Angeletti, A. Ammassari, D. Sangiorgi, A. Giannetti et al., Adherence in HIV-positive patients treated with single-tablet regimens and multi-pill regimens: findings from the COMPACT study, J Int AIDS Soc, vol.15, p.18098, 2012.

J. B. Nachega, J. Parienti, O. A. Uthman, R. Gross, D. W. Dowdy et al., Lower pill burden and oncedaily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.58, pp.1297-1307, 2014.

P. G. Clay, S. Nag, C. M. Graham, and S. Narayanan, Meta-Analysis of Studies Comparing Single and MultiTablet Fixed Dose Combination HIV Treatment Regimens, Medicine (Baltimore), vol.94, p.1677, 2015.

E. L. Wilkins, C. J. Cohen, B. Trottier, S. Esser, D. E. Smith et al., Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV1 through 48 weeks of treatment, AIDS Care, vol.28, pp.401-408, 2016.

R. Prinapori, D. Biagio, and A. , Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS, Patient Prefer Adherence, vol.9, pp.1213-1218, 2015.

S. Lambert-niclot, C. Charpentier, A. Storto, D. B. Fofana, C. Soulié et al., Prevalence of preexisting resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses, J Antimicrob Chemother, vol.68, pp.1237-1242, 2013.

J. Parienti, M. Das-douglas, V. Massari, D. Guzman, S. G. Deeks et al., Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels, PloS One, vol.3, p.18665246, 2008.

J. Parienti, V. Massari, D. Descamps, A. Vabret, E. Bouvet et al., Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine-or efavirenz-based antiretroviral therapy, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.38, pp.1311-1316, 2004.

E. F. Eaton, A. R. Tamhane, G. A. Burkholder, J. H. Willig, M. S. Saag et al., Unanticipated Effects of New Drug Availability on Antiretroviral Durability: Implications for Comparative Effectiveness Research, Open Forum Infect Dis, vol.3, p.109, 2016.